Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Predictive Oncology's Sloan Ratio for the quarter that ended in Mar. 2024 was -12.68%.
As of Mar. 2024, Predictive Oncology has a Sloan Ratio of -12.68%, indicating there is a warning stage of accrual build up.
Predictive Oncology Sloan Ratio % Historical Data
The historical data trend for Predictive Oncology's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Predictive Oncology's Sloan Ratio %
For the Medical Instruments & Supplies subindustry, Predictive Oncology's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Predictive Oncology's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Predictive Oncology's Sloan Ratio % falls into.
Predictive Oncology Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Predictive Oncology's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Predictive Oncology's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -3.923 (Jun. 2023 ) + -3.163 (Sep. 2023 ) + -3.475 (Dec. 2023 ) + -4.219 (Mar. 2024 ) = $-14.78 Mil.
Predictive Oncology's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -3.574 (Jun. 2023 ) + -3.105 (Sep. 2023 ) + -3.082 (Dec. 2023 ) + -3.416 (Mar. 2024 ) = $-13.18 Mil.
Predictive Oncology's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -0.259 (Jun. 2023 ) + -0.004 (Sep. 2023 ) + 0.007 (Dec. 2023 ) + -0.003 (Mar. 2024 ) = $-0.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Predictive Oncology (NAS:POAI) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, Predictive Oncology has a Sloan Ratio of -12.68%, indicating there is a warning stage of accrual build up.
Predictive Oncology Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Predictive Oncology's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Predictive Oncology (Predictive Oncology) Business Description
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
POAI has been successfully added to your 